Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Clinical trials and drug promotion: Selective reporting of study 329
Author: Jureidini, J.
McHenry, L.
Mansfield, P.
Citation: The International Journal of Risk and Safety in Medicine, 2008; 20(1-2):73-81
Publisher: IOS Press
Issue Date: 2008
ISSN: 0924-6479
Statement of
Jon N. Jureidini, Leemon B. McHenry, Peter R. Mansfield
Abstract: Selective reporting is prevalent in the medical literature, particularly in industry-sponsored research. In this paper, we expose selective reporting that is not evident without access to internal company documents. The published report of study 329 of paroxetine in adolescents sponsored by GlaxoSmithKline claims that “paroxetine is generally well tolerated and effective for major depression in adolescents”. By contrast, documents obtained during litigation reveal that study 329 was negative for efficacy on all 8 protocol specified outcomes and positive for harm.
Keywords: selective reporting; SSRI; litigation; industry sponsorship
RMID: 0020082755
DOI: 10.3233/JRS-2008-0426
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.